Artiva Biotherapeutics (NASDAQ:ARTV) COO Sells $79,197.90 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) COO Jennifer Bush sold 8,790 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $79,197.90. Following the transaction, the chief operating officer owned 337,920 shares of the company’s stock, valued at $3,044,659.20. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $7.99 on Friday. The company has a market capitalization of $197.51 million, a P/E ratio of -2.26 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53. The business has a 50 day moving average price of $8.40 and a 200 day moving average price of $5.70.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, research analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC grew its stake in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period. Renaissance Technologies LLC grew its stake in shares of Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after buying an additional 37,053 shares during the period. Marshall Wace LLP purchased a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at $341,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $67,000.

Wall Street Analyst Weigh In

Several analysts have commented on ARTV shares. Wedbush lifted their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Cantor Fitzgerald lifted their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Needham & Company LLC lifted their target price on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.